Journal article

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor

Srdan Verstovsek, Constantine S Tam, Martha Wadleigh, Lubomir Sokol, Catherine C Smith, Lynne A Bui, Chunyan Song, Douglas O Clary, Patrycja Olszynski, Jorge Cortes, Hagop Kantarjian, Neil P Shah

Leukemia Research | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2014